S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
Chick-fil-A Is Hiring an 'Entertainment Producer'
All the trading advice you’ve ever received boils down to this (Ad)
Dell, Marvell Technology fall; Ulta Beauty, UiPath rise, Friday, 12/1/2023
Mega merger in the works? Humana, Cigna explore big deal
All the trading advice you’ve ever received boils down to this (Ad)
MarketBeat Week in Review – 11/27 - 12/1
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
Chick-fil-A Is Hiring an 'Entertainment Producer'
All the trading advice you’ve ever received boils down to this (Ad)
Dell, Marvell Technology fall; Ulta Beauty, UiPath rise, Friday, 12/1/2023
Mega merger in the works? Humana, Cigna explore big deal
All the trading advice you’ve ever received boils down to this (Ad)
MarketBeat Week in Review – 11/27 - 12/1
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
Chick-fil-A Is Hiring an 'Entertainment Producer'
All the trading advice you’ve ever received boils down to this (Ad)
Dell, Marvell Technology fall; Ulta Beauty, UiPath rise, Friday, 12/1/2023
Mega merger in the works? Humana, Cigna explore big deal
All the trading advice you’ve ever received boils down to this (Ad)
MarketBeat Week in Review – 11/27 - 12/1
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
Chick-fil-A Is Hiring an 'Entertainment Producer'
All the trading advice you’ve ever received boils down to this (Ad)
Dell, Marvell Technology fall; Ulta Beauty, UiPath rise, Friday, 12/1/2023
Mega merger in the works? Humana, Cigna explore big deal
All the trading advice you’ve ever received boils down to this (Ad)
MarketBeat Week in Review – 11/27 - 12/1
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections

Cassava Sciences Stock Price, News & Analysis (NASDAQ:SAVA)

$20.80
-0.03 (-0.14%)
(As of 12/1/2023 ET)
Compare
Today's Range
$20.67
$21.30
50-Day Range
$12.64
$24.24
52-Week Range
$12.32
$45.43
Volume
591,297 shs
Average Volume
838,388 shs
Market Capitalization
$877.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$76.00

Cassava Sciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
265.4% Upside
$76.00 Price Target
Short Interest
Bearish
36.80% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.82
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.22) to $1.18 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

434th out of 952 stocks

Pharmaceutical Preparations Industry

200th out of 448 stocks


SAVA stock logo

About Cassava Sciences Stock (NASDAQ:SAVA)

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.

SAVA Stock Price History

SAVA Stock News Headlines

Cassava Sciences Inc SAVA
7 High-Risk, High-Reward Stocks for the Extreme Contrarian
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Cassava Sciences, Inc. (NASDAQ:SAVA): Is Breakeven Near?
IonQ Announces Third Quarter 2023 Financial Results
Ginkgo Bioworks Reports Third Quarter 2023 Financial Results
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
1 Big Red Flag to Fear When a Stock Is Down
Why Cassava Sciences Stock Surged Today
See More Headlines
Receive SAVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/02/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SAVA
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$76.00
High Stock Price Target
$124.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+265.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-76,250,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.68 per share

Miscellaneous

Free Float
38,378,000
Market Cap
$877.14 million
Optionable
Not Optionable
Beta
-0.03
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Remi Barbier (Age 63)
    Founder, Chairman, President & CEO
    Comp: $1.11M
  • Mr. Eric J. Schoen (Age 55)
    Chief Financial Officer
    Comp: $426.61k
  • Mr. R. Christopher Cook (Age 59)
    Senior VP, Company Secretary & General Counsel
    Comp: $457.64k
  • Dr. James W. Kupiec M.D. (Age 70)
    Chief Medical Officer
    Comp: $400k
  • Dr. George Thornton
    Senior Vice President of Technology
  • Mr. Michael Zamloot
    Senior Vice President of Technical Operations
  • Dr. Michael Marsman Pharm.D.
    Senior Vice President of Regulatory Affairs
  • Dr. Lindsay H. Burns Ph.D.
    Senior Vice President of Neuroscience














SAVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Cassava Sciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SAVA shares.
View SAVA analyst ratings
or view top-rated stocks.

What is Cassava Sciences' stock price target for 2024?

1 Wall Street research analysts have issued 12 month target prices for Cassava Sciences' stock. Their SAVA share price targets range from $28.00 to $124.00. On average, they expect the company's share price to reach $76.00 in the next year. This suggests a possible upside of 265.4% from the stock's current price.
View analysts price targets for SAVA
or view top-rated stocks among Wall Street analysts.

How have SAVA shares performed in 2023?

Cassava Sciences' stock was trading at $29.54 at the beginning of 2023. Since then, SAVA stock has decreased by 29.6% and is now trading at $20.80.
View the best growth stocks for 2023 here
.

When is Cassava Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our SAVA earnings forecast
.

How were Cassava Sciences' earnings last quarter?

Cassava Sciences, Inc. (NASDAQ:SAVA) released its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.61) EPS for the quarter, topping analysts' consensus estimates of ($0.90) by $0.29.

What ETFs hold Cassava Sciences' stock?
When did Cassava Sciences' stock split?

Cassava Sciences's stock reverse split on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What other stocks do shareholders of Cassava Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA).

Who are Cassava Sciences' major shareholders?

Cassava Sciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Gallacher Capital Management LLC (1.37%), Northern Trust Corp (0.89%), Charles Schwab Investment Management Inc. (0.73%), SG Americas Securities LLC (0.66%), Barclays PLC (0.00%) and Bank of New York Mellon Corp (0.32%). Insiders that own company stock include Eric Schoen, James William Kupiec, Richard Barry and Sanford Robertson.
View institutional ownership trends
.

How do I buy shares of Cassava Sciences?

Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:SAVA) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -